Affiliation:
1. Epidemiology Unit, Bari Policlinico General Hospital, 70124 Bari, Italy
2. National Institute of Gastroenterology, IRCCS S. De Bellis, Research Hospital, 70013 Castellana Grotte, Italy
Abstract
Individuals with Inflammatory Bowel Disease (IBD) are characterized by an increased vulnerability to complications stemming from infectious diseases. While these patients do not inherently face a heightened risk of SARS-CoV-2 infection compared to the general population, their vulnerability to severe COVID-19 complications and subsequent hospitalization is notably increased. The objective of our study is to quantitatively assess the global coverage of COVID-19 vaccination among individuals with IBD, achieved through a comprehensive meta-analysis and systematic review. Thirteen studies were systematically selected from scientific articles available in the MEDLINE/PubMed, ISI Web of Knowledge, and Scopus databases, spanning from 1 January 2021 to 25 July 2023. The pooled prevalence of COVID-19 vaccine uptake was estimated at 72% (95%CI = 59–83%) for at least one dose, 81% (95%CI = 68–91%) for the complete vaccination regimen, and 71% (95%CI = 46–91%) for the third dose. Analysis of the determinants influencing vaccination uptake revealed several significant associations. These encompassed Caucasian ethnicity, female sex, absence of immunosuppressive therapy, advanced age, prior receipt of the anti-influenza vaccine, absence of a history of COVID-19 infection, and the provision of advice from gastroenterologists, all linked to improved compliance. Our study underscores a noteworthy yet not entirely optimal COVID-19 vaccination coverage among individuals with IBD. A multifaceted approach is warranted to enhance vaccination rates. Within this context, the role of gastroenterologists extends beyond direct patient care, encompassing a pivotal responsibility in preventing complications stemming from post-infectious diseases.
Funder
Italian Ministry of Health
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference52 articles.
1. CDC (2023, July 24). Inflammatory Bowel Disease (IBD), Available online: https://www.cdc.gov/ibd/features/IBD-more-chronic-diseases.html.
2. The epidemiology of inflammatory bowel disease: Clues to pathogenesis?;Borowitz;Front. Pediatr.,2023
3. Caviglia, G.P., Garrone, A., Bertolino, C., Vanni, R., Bretto, E., Poshnjari, A., Tribocco, E., Frara, S., Armandi, A., and Astegiano, M. (2023). Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy. J. Clin. Med., 12.
4. Kubas, A., and Malecka-Wojciesko, E. (2022). COVID-19 Vaccination in Inflammatory Bowel Disease (IBD). J. Clin. Med., 11.
5. Health-Risk Behaviors and Chronic Conditions Among Adults with Inflammatory Bowel Disease—United States, 2015 and 2016;Xu;MMWR Morb. Mortal. Wkly. Rep.,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献